Skip to content
Screener

Stoke Therapeutics, Inc. STOK EBITDA

EBITDA at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$98.16M-169%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$518M+1,238%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$122.6M-31.0%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
-$96.87M-27.4%
CalAmp logo
CalAmpCAMP
-$12.55M+1.0%
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
$43.26M-30.5%

Other financials

Income statement

See full
Revenue$6.2M-96.1%
Operating income-$53.4M-148%
Net income-$50.0M-144%
EPS (diluted)-$0.79-142%

Balance sheet

See full
Cash & equivalents$155.7M-43.4%
Total debt$3.4M-42.5%
Total equity$394.9M+12.8%
Total assets$443.3M+8.9%

Cash flow

See full
Operating cash flow-$60.6M-146%
CapEx$353.0K+132%
Free cash flow-$60.9M-146%

Valuation

See full
Market cap$2.06B+187%
Enterprise value$1.91B+206%
P/S64.2×+60.6×

Profitability

See full
Operating margin-577.5%-597pp
Net margin-529.2%-556pp
FCF margin36.2%+18.4pp

Returns & leverage

See full
Return on equity-45.6%-66.1pp
Debt / equity0×0.0×
Current ratio9×+0.6×

Where this comes from

Calculated from Stoke Therapeutics, Inc.’s reported figures.

−$53.4Mebit+
$439.0KDepreciation Depletion & Amortization
=-$52.98M

The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026. Open the filing →

Filed
May 7, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211874

FAQ

What is Stoke Therapeutics, Inc.'s EBITDA?
Stoke Therapeutics, Inc. (STOK) reported EBITDA of -$52.98M in Q1 2026.
How has Stoke Therapeutics, Inc.'s EBITDA changed year-over-year?
Stoke Therapeutics, Inc.'s EBITDA decreased by 147.4% year-over-year, from $111.72M to -$52.98M.
What is the long-term trend for Stoke Therapeutics, Inc.'s EBITDA?
Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s EBITDA has grown at a -31.4% compound annual growth rate (CAGR), from -$85.09M to -$18.82M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

Ask your AI about Stoke Therapeutics, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude